Solid Tumor Research
Ongoing Research
Researchers are investigating alternative ways to assess renal function in children with cancer, performing a detailed assessment using functional dynamic imaging of the kidneys and studying cystatin C, a biomarker for renal function that is not affected by diet or muscle mass.
Researchers are studying the pharmacokinetic properties of two common chemotherapeutic compounds to determine optimum dosing for these medications in infants.
CHD5, a gene located on the distal portion of the short arm of chromosome 1, may function as a tumor suppressor gene and contribute to the development of malignant neuroblastoma when deleted.
Research in the laboratory of Kristina A Cole, MD, PhD involves identifying the proteins required for malignant gliomas with alternative lengthening of telomeres (ALT) to continue to proliferate.
Researchers at the Center for Childhood Cancer Research are working to generate a series of position papers intended to detail the recommended best practices for pediatric cancer surveillance.
Cancer therapy during childhood including chemotherapy, radiation, and/or hematopoietic stem cell transplantation (HSCT) result in long-term late effects, which require prompt diagnosis, treatment and management following completion of cancer therapy.
Researchers are assessing the use of an RNA-modified form of chimeric antigen receptor (CAR) T cells to treat refractory and relapsed neuroblastoma.
At the Center for Childhood Cancer Research, our experts are studying how the body handles biologics in order to enhance our ability to best use these biological agents in the overall treatment of childhood cancer.
A clinical trial is currently underway through the COG to evaluate the safety and efficacy combining a Wee1 inhibitor AZD-1775 and Irinotecan as treatment for relapsed and refractory neuroblastoma and medulloblastoma.
Inhibition of the TRK tyrosine kinase family has shown enduring response in clinical trials and efforts are underway to assess newer TRK inhibitors.
Researchers are currently enrolling patients for this Phase III trial assessing the addition of the radiopharmaceutical MIBG to standard care for high-risk neuroblastoma.
Incorporating biomarkers that sensitively measure drug toxicity and tumor burden as clinical trial endpoints has the potential to shorten the timeline to develop new treatments for childhood cancers.
Identifying new biomarkers that reflect the body’s capacity to break down and eliminate anticancer drugs could lead to more accurate dosing methods and improve the safety and efficacy of anticancer drugs in children.